Key Takeaways:
Amneal Pharmaceuticals Inc. (AMRX) will acquire Kashiv BioSciences for $750 million in a cash-and-stock deal, creating a fully integrated platform for biosimilar drugs ahead of a major patent cliff.
"With Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines," Chirag Patel, Co-Founder and Co-Chief Executive Officer of Amneal, said. "This acquisition is a natural next step in our strategy to build a leading, diversified biopharmaceutical company."
The transaction includes $375 million in cash and $375 million in Amneal stock, with an additional $350 million in potential milestone-based payments. The deal announcement coincided with Amneal reporting preliminary first-quarter adjusted EBITDA of $202 million, a 19% increase from the prior year, and raising its full-year 2026 adjusted EBITDA guidance to a range of $740 million to $770 million.
The acquisition positions Amneal to capitalize on a wave of biologics losing patent exclusivity, a market opportunity estimated at over $300 billion in the next decade. The deal is expected to close in the second half of 2026, subject to shareholder and regulatory approval.
By acquiring Kashiv, Amneal gains an end-to-end biosimilars platform, from research and development to manufacturing. Kashiv has a proven track record in developing and manufacturing complex medicines. The combination is designed to leverage Kashiv's R&D engine with Amneal's large-scale commercial capabilities in the U.S. market. "Our companies share a deep-rooted commitment to high-quality, complex medicines," said Dr. Sandeep Athalye, CEO at Kashiv.
Amneal enters the transaction from a position of financial strength. The company reported preliminary Q1 2026 net revenue of $723 million, up 4% year-over-year, driven by a 23% surge in its Specialty segment. Adjusted diluted earnings per share for the quarter were $0.27, a 29% increase compared to the same period last year. The company's stock rose over 5% in pre-market trading following the news.
The acquisition is a significant step in Amneal's strategy to diversify and accelerate its growth. For investors, the deal represents a clear move to capture a larger share of the rapidly expanding biosimilars market. The next major catalyst will be the shareholder vote and the subsequent regulatory review process expected in the coming months.
This article is for informational purposes only and does not constitute investment advice.
